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Abstract Gemcitabine is a chemotherapy agent that may
cause unpredictable side eVects. In this report, we describe
a fatal gemcitabine-induced pulmonary toxicity in a patient
with gallbladder metastatic adenocarcinoma. A 72-year-old
patient was submitted to an elective laparoscopic cholecys-
tectomy, and a tubular adenocarcinoma in the gallbladder
was incidentally diagnosed. CT scan and ultrasound before
the surgery did not show any tumor. After the surgery a
Pet scan was positive for a hot-spot in the left colon.
The colonic lesion was conveniently removed and the his-
tology evaluation conWrmed the diagnosis of adenocarci-
noma tubular. The patient was then submitted to three
sections of 1,600 mg/m2 of gemcitabine with intervals of
1 week. Three weeks later he developed severe respiratory
distress. A helicoidal CT scan showed diVuse and severe
interstitial pneumonitis, and lung biopsy conWrmed accelerated
usual interstitial pneumonia consistent with drug-induced
toxicity. The patient presented unfavorable evolution with
progressive worsening of respiratory function, hypotension,
and renal failure. He died 1 month later in spite of methyl-
prednisolone pulse therapy, large spectrum antimicrobial
therapy, and full support of respiratory, hemodynamic and
renal systems. Gemcitabine-induced pulmonary toxicity is
usually a dramatic condition. Physicians should suspect
pulmonary toxicity in patients with respiratory distress after
gemcitabine chemotherapy, mainly in elderly patients.
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Introduction
Gemcitabine is a chemotherapy agent frequently elected to
treat solid tumors, including breast, colonic, ovarian, pan-
creatic, and non-small cell lung cancers [1–12]. Its side
eVect is unpredictable and lung toxicity has been observed
[1–13]. Metastatic gallbladder cancer is a complex and
uncommon event [14–17]. In this report, we describe a case
of gallbladder metastatic colonic adenocarcinoma associ-
ated with fatal gemcitabine-induced pulmonary toxicity and
discuss the histologic appearance of this dysfunction.
Case report
A 72-year-old male patient experienced an incidental diag-
nostic of tubular adenocarcinoma inside the gallbladder
after elective laparoscopic cholecystectomy for chronic
cholecystitis. CT scan and ultrasonographic evaluations
performed before surgery were negative. Four days after
cholecystectomy, he was submitted to laparotomy aiming
radical resection; however, peritoneal carcinomatosis was
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608 Cancer Chemother Pharmacol (2010) 65:607–610observed. The patient was submitted to a tumor screening
and a Pet scan pointed out a hot-spot in the left colon. This
lesion was removed by colonoscopy and a histological
examination conWrmed a margin-free resection of a tubular
adenocarcinoma. The patient was Wnally scheduled to
receive three sections of gemcitabine (1,600 mg/m2) once a
week. Three weeks after the completion of chemotherapy,
he developed an important respiratory distress requiring
ventilator support. A helicoidal CT scan showed bilateral
and diVuse lung inWltrates (Fig. 1). A surgical lung biopsy
was done and an accelerated usual interstitial pneumonia
(UIP) (Fig. 2), consistent with drug-induced toxicity, was
observed. The patient presented with progressive impairment
of respiratory function, coagulopathy, hypotension, and acute
renal failure despite the use of methylprednisolone pulse
therapy, large spectrum antimicrobial therapy, and full
respiratory, hemodynamic and dialytic support. He died
1 month later. To assess the probability that the event was
caused by gemcitabine we computed a Naranjo et al. [18]
average point score, which is based on the direction of cau-
sality between the drug and the manifestation of adverse
eVects. Naranjo’s method estimates gemcitabine as the
probable cause of pulmonary toxicity in the current report.
Comments
There are several papers reporting pulmonary toxicity due
to gemcitabine used as a single agent [1–8] or in combina-
tion with other antineoplastic agents [9–13]. The treatment
Fig. 1 a Coronal reformatted 
images demonstrate involve-
ment of all lung zones and pre-
dominantly upper lobe 
distribution of the ground-glass 
opacities and areas of consolida-
tion. Also noted are reticulation 
and small cysts in the subpleural 
and basal regions of the lungs. 
b High-resolution CT image at 
the level of the main bronchi 
shows extensive bilateral 
ground-glass opacities and 
dependent areas of consolida-
tion. Some emphysema can also 
be seen
Fig. 2 Lung surgical biopsy 
specimen showing accelerated 
usual interstitial pneumonia 
(UIP). A characteristic area of 
honeycomb change is shown at 
low magniWcation (a). At lower 
left corner (a), the adjacent alve-
olar septa are homogeneously 
thickened by Wbroblast and 
chronic inXammation. Higher 
magniWcation of area showed in 
lower left corner (b, c) high-
lights the Wbroblasts and chronic 
inXammation within alveolar 
septa and shows associated hya-
line membranes (arrow). The 
appearance coincides with the 
organizing stage of DAD. Note 
also the squamous metaplasia 
(arrows) of bronchiolar epithe-
lium from adjacent honeycomb 
area (d). This Wnding is another 
sign of superimposed acute lung 
injury123
Cancer Chemother Pharmacol (2010) 65:607–610 609of this event includes early use of steroid therapy adminis-
tered either as pulses or continuously [1], mainly using
methylprednisolone; nevertheless, most cases have a dra-
matic and fatal evolution. Our patient obtained fatal evolu-
tion in spite of the use of steroids as recommended in the
literature.
Belknap et al. [3], reviewed data from spontaneous
reports to Research on Adverse Drug Events and Reports of
pharmacovigilance (RADAR) program and appraised the
clinical feature of gemcitabine-associated severe acute lung
injury. Among 178 reports of gemcitabine-induced pulmo-
nary injury (55 from clinical trials and 92 from spontaneous
reports) dyspnea, fever, and pulmonary inWltrate were the
most frequent symptoms of gemcitabine-induced pulmo-
nary injury [3]. The median time to the diagnosis of this
toxicity is 48 days (range 1–529) after initiation of gemcita-
bine.
Taxanes, docetaxel, and paclitaxel were the most fre-
quent co-administered chemotherapies [3]. Eleven phase II
or phase III clinical trials enrolling 317 patients identiWed
pulmonary injury rates greater than 10% [3]. Highest rates
of this toxicity (22 and 42%) were observed in phase III
clinical trials in which patients with Hodgkin’s disease
were treated with gemcitabine and bleomycin [3].
The authors concluded that high rates of gemcitabine-
associated severe lung injury were observed, mainly when
gemcitabine was combined with other agents that can also
cause lung injury [3]. Just recently, Arrieta et al. [13],
observed that radiotherapy and gemcitabine for locally
advanced non-small cell lung cancer is associated with
excessive pulmonary toxicity.
DiVerently, Czarnecki and Voss [12] reviewed records
of patients with pulmonary toxicity at FDA freedom of
information (FDA-FOI) database and observed that there
was no substantial diVerence in pulmonary toxicity with the
combination of gemcitabine and taxanes in comparison
with gemcitabine alone. Indeed, gemcitabine-induced pul-
monary toxicity is a dramatic condition. In the current case,
the patient presented with rapidly progressive respiratory
failure and the lung biopsy showed an accelerated UIP
complicated by superimposed acute lung injury. Most
reported cases have occurred in patients with known UIP,
but the lesion can occur in patients with clinically unrecog-
nized UIP [18]. The etiology of acute lung injury in UIP is
unknown, but most cases are assumed to represent an inher-
ent part of the natural history of UIP. Histologically, how-
ever, the changes cannot be separated from other causes of
acute lung injury (such as viral infections, aspiration, sep-
sis, drug reactions, or toxic inhalants), and it is entirely pos-
sible that some cases may represent reactions to clinically
unrecognized extrinsic lung insults [19]. Pathologically, the
diagnosis is not usually diYcult if all microscopic changes
are taken into consideration. Classically, there are easily
recognizable areas of UIP with patchwork pattern and hon-
eycomb change. Focus of diVuse alveolar damage (DAD)
recognizable by larger and more conXuent interstitial Wbro-
blast proliferation smaller than Wbroblast foci of UIP are
usually present [19]. Hyaline membranes are also present
and they make easy diagnosis. Other Wndings of the diagno-
sis include squamous metaplasia in bronchiolar epithelium
lining honeycomb areas. In the current case, Naranjo’s
method identiWed gemcitabine as the probable agent of pul-
monary toxicity.
The liver is the most common site of metastatic dissemi-
nation of a colonic tumor; however, a tumor from this
region is very rare. In fact, this is the Wrst report of metasta-
size inside the gallbladder from a tumor of colon origin.
There are few reports describing gallbladder metastasize
from other origins [13–16]. The prognostic of these patients
was very poor with most of them achieving <1-year sur-
vival.
In summary, physicians should suspect pulmonary toxic-
ity in patients with respiratory distress after gemcitabine
chemotherapy, mainly in elderly patients that received high
doses of this drug.
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